Home › NDC Lookup › Ingredients › Tobramycin › 61314-0643-05
👁️image loading
(from DailyMed)

Tobramycin 3 mg/mL Solution, 5 mL — NDC 61314-643-05 (Billing 61314-0643-05)

by Sandoz Inc · 5 mL in 1 BOTTLE, PLASTIC

This is a package of 5 mL of Tobramycin 3 mg/mL Solution from Sandoz Inc, marketed since Jan 1995 and currently FDA-listed; retail pharmacies pay about $1.11 per mL (NADAC). It is this product's only package size.

NDC 61314-0643-05
🏷️ FDA NDC (as labeled) 61314-643-05 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 61314-643-05 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
61314 labeler · 643 product · 05 package
Package marketed since
Jan 9, 1995
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
5 mL per package
Barcode (UPC)
0361314643056
Medicaid fills, this package
27,901 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 61314-643-05
Product NDC 61314-643
11-digit billing NDC 61314064305
NCPDP billing unit ML — per mL (volume)
RxCUI 313415
UNII VZ8RRZ51VK
UPC 0361314643056
Application # ANDA062535
SPL Set ID 27e2c16e-19b0-4745-93eb-5cf99f94bb92
Established class (EPC) Aminoglycoside Antibacterial
Chemical class Aminoglycosides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1995-01-09
Route OPHTHALMIC
Dosage form SOLUTION
Substance TOBRAMYCIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86101070002005
GPI class Tobramycin
GCN Seq No 038588
GCN 09384
HICL code 017765
Ingredient (HICL) Tobramycin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.02.00
AHFS class Aminoglycoside Antibiotics
FDB label name TOBRAMYCIN 0.3% EYE DROP
FDB brand name Tobramycin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 038588
  • GCN: 09384
  • GPI-14 (Medi-Span): 86101070002005
  • HICL (First Databank): 017765
  • AHFS class code: 08:12.02.00
  • RxCUI (RxNorm): 313415
Why two NDCs? The FDA registers this code as 61314-643-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 61314-0643-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Aminoglycoside Antibacterial class.

Pharmacologic class Aminoglycoside Antibacterial
Drug family (ATC) Other aminoglycosides, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TOBRAMYCIN 0.3% EYE DROP Ingredient Tobramycin
📗 Our plain-language guide HelloPharmacist
  • It depends on the form. Inhaled tobramycin treats Pseudomonas aeruginosa lung infection in cystic fibrosis. Eye drops and ointment treat external eye infections. The injection trea...
  • You breathe it in by mouth, usually twice a day about 12 hours apart, for 28 days. Then you take 28 days off. TOBI Podhaler capsules must never be swallowed; they are used only wit...
  • Cough, shortness of breath, fever, sore throat, hoarseness and headache are common with the inhaled form. Mention them to your care team if they bother you.
  • Call about ringing in the ears, hearing loss, dizziness or balance trouble, new muscle weakness, or wheezing after a dose. These can be signs of serious effects.
📖 Read our full Tobramycin guide →
8
Nutrient depletion considerations

Tobramycin may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Tobramycin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $1.108 $5.54 / 5 ml
Medicaid paysCMS SDUD · 12 mo $2.21 $11.05 / 5 ml
Medicare drug plans payPart D · Q2 2026 $0.9370 $4.69 / 5 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $1.805 $1.002
▼ Down 8% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
61314-0643-05 You're viewing this Main listing 5 mL in 1 BOTTLE, PLASTIC 1995-01-09 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tobramycin 3 mg/mL 24208-0290-05 Bausch 1 bottle $1.108 AT Availability likely —
Tobramycin 3 mg/mLthis 61314-0643-05 Sandoz 5 ml $1.108 AT Availability likely —
Tobramycin Ophthalmic Solution 3 mg/mL 62332-0518-05 Alembic 1 bottle $1.108 AT Availability likely —
Tobramycin 3 mg/mL 70069-0131-01 Somerset 1 bottle $1.108 AT Availability likely —
Tobramycin Ophthalmic Solution 3 mg/mL 46708-0518-05 Alembic 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 50090-2127-00 A-S 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 50090-4190-00 A-S 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 60760-0583-05 St. 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 61919-0642-05 DirectRX 5 ml — AT FDA listed —
Tobramycin 3 mg/mL 62250-0110-01 Belcher 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 63187-0024-05 Proficient 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 63187-0902-02 Proficient 1 bottle — — FDA listed —
Tobramycin 3 mg/mL 63187-0973-05 Proficient 5 ml — AT FDA listed —
Tobramycin 3 mg/mL 66267-0936-05 NuCare 5 ml — AT FDA listed —
Tobramycin 3 mg/mL 68071-2272-05 NuCare 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 68083-0374-01 Gland 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 68788-7252-05 Preferred 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 70518-1370-00 REMEDYREPACK 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 71205-0101-05 Proficient 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 76420-0092-05 Asclemed 5 ml — AT FDA listed —
Tobramycin 3 mg/mL 76420-0791-05 Asclemed 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 80425-0341-01 Advanced 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 85766-0025-05 Sportpharm 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 85766-0189-05 Sportpharm 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 86211-0110-01 JVET 1 bottle — AT FDA listed —
Tobramycin 3 mg/mL 68788-4149-05 Preferred 1 bottle — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1995
On the market since
Jan 1995
📍
2026
Currently FDA-listed
31 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Tobramycin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 0YPR65R21J
    Sodium sulfate is a mineral salt used in pharmaceuticals as a filler and diluent. It helps provide bulk and stability to tablets and capsules while remaining inert in the body.
  • UNII O40UQP6WCF
    A strong acid used in small amounts to adjust and maintain the pH balance of a medicine, helping ensure stability and proper dissolution of the active ingredients.
  • UNII Y27PUL9H56
    Tyloxapol is a synthetic detergent and surfactant used in medications as a solubilizer and emulsifier. It helps dissolve or blend ingredients that don't naturally mix well, improving how the medicine disperses in liquid formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSandoz Inc
Application holderSANDOZ INC
FDA applicationANDA062535 (ANDA)
Labeler code61314
First marketedJan 1995
Product typeHuman Prescription Drug
Portfolio391 products on file

More NDCs from Sandoz Inc labeler code 61314

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 60 words ▾

INDICATIONS AND USAGE Tobramycin ophthalmic solution, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

⏱️ Dosage and Administration 41 words ▾

DOSAGE AND ADMINISTRATION In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS Tobramycin ophthalmic solution, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

⚠️ Warnings 58 words ▾

WARNINGS FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution, 0.3% occurs, discontinue use.

🤒 Adverse Reactions 127 words ▾

ADVERSE REACTIONS The most frequent adverse reactions to tobramycin ophthalmic solution, 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution, 0.3%. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Postmarketing Experience Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme. The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

🤰 Pregnancy 66 words ▾

Pregnancy Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

🧒 Pediatric Use 18 words ▾

Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

🧓 Geriatric Use 18 words ▾

Geriatric Use No overall clinical differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology 93 words ▾

CLINICAL PHARMACOLOGY In Vitro Data In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

📦 How Supplied / Storage and Handling 69 words ▾

HOW SUPPLIED Tobramycin ophthalmic solution, USP 0.3% is supplied as a 5 mL sterile solution, packaged in a 8 mL white plastic bottle with a plastic dispensing plug and white plastic closure as follows: 5 mL containing tobramycin 0.3% (3 mg/mL) NDC 61314-643-05 Storage Store at 2° to 25°C (36° to 77°F). After opening, tobramycin ophthalmic solution, USP 0.3% can be used until the expiration date on the bottle.

📋 Description 121 words ▾

DESCRIPTION Tobramycin ophthalmic solution, USP 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections. Each mL of tobramycin ophthalmic solution, USP 0.3% contains: Active: tobramycin 0.3% (3 mg). Preservative: benzalkonium chloride 0.01% (0.1 mg).

Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and purified water. Tobramycin ophthalmic solution, USP 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is: MW=467.52 Molecular Formula: C 18 H 37 N 5 O 9 Chemical Name: 0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4)} -0- {2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→6) }-2-deoxystreptamine. chemical

💬 Information for Patients 17 words ▾

Information for Patients Do not touch dropper tip to any surface, as this may contaminate the solution.

⚠️ Precautions ~1 min read ▾

PRECAUTIONS General As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy.

Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular infection. Information for Patients Do not touch dropper tip to any surface, as this may contaminate the solution. Pregnancy Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 months has not been established. Geriatric Use No overall clinical differences in safety or effectiveness have been observed between elderly and younger patients.

🍼 Nursing Mothers 43 words ▾

Nursing Mothers Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

📄 Package Label / Principal Display Panel 17 words ▾

PRINCIPAL DISPLAY PANEL NDC 61314-643-05 Tobramycin Ophthalmic Solution, USP 0.3% Rx only STERILE 5 mL SANDOZ 5mlcarton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
27.9K
Units reimbursed last 4 qtrs
149.1K
Gross reimbursed last 4 qtrs
$329.5K
Avg / prescription
$11.81
Avg / unit
$2.2095
Latest quarter Q1 2026
6.2KRx
Medicaid pays / mL
$2.2095
gross reimbursed
vs
NADAC / mL
$1.1081
acquisition cost
=
Spread
+$1.1014
+99% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
34% FFS 66% MCO
Fee-for-service · 9,470 Rx Managed care · 18,431 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 1,225 units · 15.7 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 291 units · 5.1 per 100k residents MN Wisconsin: no data reported WI Michigan: 745 units · 7.4 per 100k residents MI New York: 4,625 units · 23.6 per 100k residents NY Vermont: no data reported VT New Hampshire: 487 units · 34.7 per 100k residents NH Oregon: 546 units · 12.9 per 100k residents OR Nevada: 4,255 units · 133 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 350 units · 2.8 per 100k residents IL Indiana: 456 units · 6.6 per 100k residents IN Ohio: 710 units · 6.0 per 100k residents OH Pennsylvania: 960 units · 7.4 per 100k residents PA New Jersey: 1,095 units · 11.8 per 100k residents NJ Massachusetts: 4,522 units · 64.6 per 100k residents MA California: 36,474 units · 93.6 per 100k residents CA Utah: 460 units · 13.5 per 100k residents UT Colorado: 60 units · 1.0 per 100k residents CO Nebraska: 145 units · 7.3 per 100k residents NE Missouri: 237 units · 3.8 per 100k residents MO Kentucky: 2,373 units · 52.4 per 100k residents KY West Virginia: no data reported WV Virginia: 3,227 units · 37.0 per 100k residents VA Maryland: 3,283 units · 53.1 per 100k residents MD Connecticut: 5,330 units · 147 per 100k residents CT Rhode Island: 1,075 units · 98.2 per 100k residents RI Arizona: 6,960 units · 93.7 per 100k residents AZ New Mexico: 230 units · 10.9 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,725 units · 24.2 per 100k residents TN North Carolina: 5,332 units · 49.2 per 100k residents NC South Carolina: 150 units · 2.8 per 100k residents SC Delaware: no data reported DE Oklahoma: 1,175 units · 29.0 per 100k residents OK Louisiana: 2,265 units · 49.5 per 100k residents LA Mississippi: 401 units · 13.6 per 100k residents MS Alabama: 880 units · 17.2 per 100k residents AL Georgia: 6,475 units · 58.7 per 100k residents GA D.C.: 327 units · 48.2 per 100k residents DC Hawaii: 1,830 units · 128 per 100k residents HI Texas: 22,505 units · 73.8 per 100k residents TX Florida: 25,247 units · 112 per 100k residents FL
Units reimbursed · per 100k residents
1.0147
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 147 /100k
2 Nevada 133 /100k
3 Hawaii 128 /100k
4 Florida 112 /100k
5 Rhode Island 98.2 /100k
6 Arizona 93.7 /100k
7 California 93.6 /100k
8 Texas 73.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Tobramycin — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Tobramycin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$564.7K
Claims incl. refills
354
Beneficiaries
253
Spend / beneficiary
$2,232.06
Spend / claim
$1,595.23
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 61314-0641-75 · Sandoz 61314-0645-11 · Sandoz →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.